With an aim to improve the healthcare system for patients, Belgium-based Novalis Biotech, an early-stage VC investor in healthtech sector, has successfully closed the first round of its second fund, Novalis Biotech Acceleration, raising an initial €8M. The majority of investors in Novalis’ first fund have co-invested in this first closing.
The fund also claims to have commitments for a similar amount to be raised soon; anticipates a final closing in early 2021. “We have already doubled our first fund in this closing, and with the commitments, in place, we are almost fully subscribed to reach our goal of €25M. With the addition of a couple of new investors, we remain on track to fully close the Acceleration Fund in early 2021,” says Jan Van den Berghe, co-founder of Novalis.